Sncatm2.1(SNCA*)Ge
Targeted Allele Detail
|
|
| Symbol: |
Sncatm2.1(SNCA*)Ge |
| Name: |
synuclein, alpha; targeted mutation 2.1, Gregor Eichele |
| MGI ID: |
MGI:7572835 |
| Synonyms: |
halphaSyndelta119 |
| Gene: |
Snca Location: Chr6:60708559-60806839 bp, - strand Genetic Position: Chr6, 29.15 cM
|
| Alliance: |
Sncatm2.1(SNCA*)Ge page
|
|
| Germline Transmission: |
Earliest citation of germline transmission:
J:314280
|
| Parent Cell Line: |
Not Specified (ES Cell)
|
| Strain of Origin: |
129
|
|
| Allele Type: |
|
Targeted (Humanized sequence, Inserted expressed sequence) |
| Mutation: |
|
Insertion
|
| |
|
Sncatm2.1(SNCA*)Ge expresses
1 gene
Knock-in expresses:
| Organism |
Expressed Gene |
Homolog in Mouse |
Note |
| human |
SNCA (6622) |
|
Expresses a mutant C-terminally truncated human SNCA |
|
| |
|
Mutation details: A targeting vector consisting of loxP-flanked human alpha-synuclein, followed by a C-terminally truncated human alpha-synuclein lacking 21 amino acids, IRES, a placental alkaline phosphatase (pLAP)reporter gene, and an FRT-flanked neomycin gene was targeted to exon 3. The neomycin selection cassette was removed via flp-mediated recombination. Cre-mediated recombination removed the human alpha-synuclein resulting in the expression of the C-terminally truncated protein. RT-PCR confirmed the expression of the expected 503 bp human mutant transcript. The truncation terminates with aspartic acid at residue 119 (120 CCT to TAA) and favors fibrillary aggregate formation.
(J:314280)
|
|
|
| Mouse strains and cell lines
available from the International Mouse Strain Resource
(IMSR) |
| Carrying this Mutation: |
Mouse Strains: 0 strains available
Cell Lines: 0 lines available
|
| Carrying any Snca Mutation: |
42 strains or lines available
|
|
| Original: |
J:314280 Martinez Hernandez A, et al., Low-Expressing Synucleinopathy Mouse Models Based on Oligomer-Forming Mutations and C-Terminal Truncation of alpha-Synuclein. Front Neurosci. 2021;15:643391 |
| All: |
1 reference(s) |
|
Analysis Tools
